Related Experiment Video

Updated: Apr 4, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

Karim Fizazi1, Laurence Albiges, Yohann Loriot

  • 1a Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, 114 rue Edouard Vaillant, 94800 Villejuif, France.

Expert Review of Anticancer Therapy
|August 28, 2015
PubMed

Insights

New androgen receptor (AR) inhibitors like ODM-201 show promise for treating castration-resistant prostate cancer (CRPC). The ARAMIS trial investigates ODM-201 for non-metastatic CRPC, a stage lacking approved treatments.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Androgen deprivation therapy (ADT) is standard for advanced hormone-sensitive prostate cancer.
  • Most patients eventually progress to castration-resistant prostate cancer (CRPC).
  • CRPC remains dependent on androgen receptor (AR) signaling, driving development of new therapies.

Purpose of the Study:

  • To review ODM-201, a novel AR inhibitor for CRPC treatment.
  • To discuss the design of the Phase III ARAMIS trial for ODM-201 in non-metastatic CRPC.

Main Methods:

  • Review of existing literature on AR inhibitors.
  • Description of the ARAMIS trial design for ODM-201 in non-metastatic CRPC.

Main Results:

  • Abiraterone acetate and enzalutamide have demonstrated improved survival in CRPC.
  • ODM-201 is a new-generation AR inhibitor with a unique structure.
  • The ARAMIS trial is evaluating ODM-201 in a patient population with no current approved treatments.

Conclusions:

  • New AR inhibitors represent a significant advancement in CRPC treatment.
  • ODM-201 shows potential for treating CRPC, particularly in the non-metastatic setting.
  • The ARAMIS trial will provide crucial data on ODM-201 efficacy and safety.
Keywords:
ODM-201androgen receptor inhibitorscastration resistantefficacymetastaticnon-metastaticpharmacodynamicspharmacokineticsprostate cancertolerability

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
Serum and Plasma Copy Number Detection Using Real-time PCR09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.9K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K